Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7743 pages
Showing 1 - 50All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia
As reported in the Journal of Clinical Oncology by Platzbecker et al, the European intergroup phase III APOLLO trial showed that an all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO; ATRA-ATO)–based regimen was associated with improved event-free survival vs a standard ATRA plus...
GLP-1 RAs and Cancer Risk in Adults With Overweight/Obesity
In a retrospective study reported in JAMA Oncology, Dai et al found that use of GLP-1 receptor agonists (GLP-1 RAs) for weight loss in adults with overweight/obesity was associated with an overall reduction in risk of cancer. As stated by the investigators, “…GLP-1 RAs… are widely prescribed for...
Model to Identify Patients With Clinical High-Risk Early Breast Cancer Who May Avoid Escalated Adjuvant Therapy
As reported in the Journal of Clinical Oncology, Bidard et al developed a model that may identify a subgroup of patients with clinical high-risk estrogen receptor (ER)-positive/HER2-negative early breast cancer who might derive no additional distant recurrence benefit from escalation of adjuvant...
AI Shear Wave Elastography Model for Diagnosing Breast Cancer in BI-RADS 3 or 4 Masses
In a study (INSPiRED 006) reported in the Journal of Clinical Oncology, Cai et al found that an artificial intelligence–guided shear wave elastography (AI-SWE) model provided accuracy similar to expert reading of B-mode ultrasound in the diagnosis of breast cancer in women with Breast Imaging...
Public Awareness of HPV, HPV Vaccine, and the Association of HPV With Cancer
In a U.S. state-level study reported as a research letter in JAMA Oncology, Garg et al found that awareness of human papillomavirus (HPV), HPV vaccination, and the association between HPV infection and development of cancers was “overwhelmingly low.” As stated by the investigators, “Each year, an...
Addition of Sintilimab to Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer
In a Chinese single-center phase II trial (SPRING-01) reported in The Lancet Oncology, Tian et al found that the addition of the PD-1 inhibitor sintilimab to chemotherapy following short-course radiotherapy as part of total neoadjuvant treatment significantly improved the pathologic complete...
Conversion of Unresectable Into Resectable Pancreatic Cancer: Chemoradiotherapy vs Chemotherapy
In a German phase III trial (CONKO-007) reported in the Journal of Clinical Oncology, Fietkau et al found that although adding chemoradiotherapy (CRT) to chemotherapy vs chemotherapy alone following induction therapy did not improve overall R0 resection rate in all patients with initially...
Mifamurtide Plus Chemotherapy for Nonmetastatic High-Grade Osteosarcoma
In a pooled analysis of the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) trials reported in the Journal of Clinical Oncology, Palmerini et al found evidence of activity with the addition of mifamurtide to chemotherapy in patients with nonmetastatic high-grade osteosarcoma...
Lu-177 Dotatate in Progressive Metastatic Pheochromocytomas and Paragangliomas
In an interim analysis of a National Institutes of Health phase II study reported in the Journal of Clinical Oncology, Lin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) was active in progressive metastatic pheochromocytomas and paragangliomas (PPGLs). As stated by the investigators,...
Disparities in U.S. County–Level Cervical Cancer Screening Coverage Lead to Differences in Outcomes
In a study reported as a research letter in JAMA Network Open, Amboree identified U.S. counties with low or high cervical cancer screening coverage and associated risks of cervical cancer incidence and mortality. As stated by the investigators, “Recent research shows that cervical cancer incidence...
Association of Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms in Childhood Cancer Survivors
In an analysis from the Children’s Oncology Group ALTE03N1 Study reported in the Journal of Clinical Oncology, Zhou et al found a fourfold increased risk of subsequent neoplasms (SNs) among childhood cancer survivors with germline pathogenic/likely pathogenic (P/LP) mutations. Study Details The...
Pembrolizumab Plus Chemotherapy vs Chemotherapy in Advanced Gastric Cancers: Final Survival Analysis From KEYNOTE-585
As reported in the Journal of Clinical Oncology by Shitara et al, the final overall survival analysis from the phase III KEYNOTE-585 study showed a numeric—but statistically nonsignificant—benefit with pembrolizumab plus chemotherapy vs chemotherapy in perioperative therapy for patients with...
Identification of FAP-Expressing Tumors With Radiotracer
In a German single-center phase II trial reported in The Lancet Oncology, Pabst et al found that use of the fibroblast activation protein α (FAP)–directed radiotracer Ga-68–FAPi-46 for positron-emission tomography-computed tomography (PET-CT) has shown promising ability to identify FAP-expressing...
Adagrasib vs Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C–Mutated NSCLC
As reported in The Lancet by Barlesi et al, the phase III KRYSTAL-12 trial has shown a significant progression-free survival benefit with adagrasib over docetaxel in patients with previously treated locally advanced or metastatic KRAS G12C–mutated non–small cell lung cancer (NSCLC). Study Details...
Rural and Urban Differences in Prostate Cancer Recurrence
In a study reported in JAMA Network Open, Balmaceda et al found that rural patients in North Carolina with newly diagnosed prostate cancer were more likely to experience biochemical recurrence than were urban patients. Study Details This cohort study used data from the North Carolina Prostate...
Metastatic Colorectal Cancer: PROs With Sotorasib and Panitumumab vs Standard of Care
In an analysis from the phase III CodeBreaK 300 study reported in The Lancet Oncology, Modest et al found that sotorasib and panitumumab were associated with better patient-reported outcomes (PROs) than standard of care (SOC) with trifluridine plus tipiracil or regorafenib in patients with KRAS...
Locoregionally Advanced Nasopharyngeal Carcinoma: Comparison of Regimens Following Induction Chemotherapy
In a Chinese phase III trial reported in JAMA Oncology, Xue et al found that sequential chemoradiotherapy (SCRT) was noninferior to induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) in terms of failure-free survival in patients with locoregionally advanced nasopharyngeal...
Effect of Hippocampal Avoidance in Prophylactic Cranial Irradiation in SCLC
In a phase II/III trial (NRG-CC003) reported in the Journal of Clinical Oncology, Gondi et al found that hippocampal avoidance (HA) in prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) did not improve delayed recall failure but was associated with benefits in...
Endocrine Therapy With Aromatase Inhibitor for Postmenopausal Women With Breast Cancer
In a patient-level meta-analysis reported in The Lancet, Braybrooke et al of the Early Breast Cancer Trialists’ Collaborative Group found that adding subsequent years of aromatase inhibitor treatment (AIT) for women with early estrogen receptor–positive breast cancer who had already received 5...
EBRT With Focal Boost in Localized Prostate Cancer: 10-Year Follow-up
As reported in the Journal of Clinical Oncology by Guricová et al, 10-year outcomes of the Dutch-Belgian phase III FLAME trial showed continued benefit of a focal radiotherapy boost to the intraprostatic tumor in patients receiving external-beam radiotherapy (EBRT) for localized prostate cancer....
Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods
In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre–COVID-19 period, with no significant difference in recurrence or progression being observed. Study ...
Age Threshold for Survival Benefit of Adding Oxaliplatin to Adjuvant Chemotherapy in Stage II and III Colorectal Cancer
In a Korean retrospective study reported in JAMA Network Open, Bong et al found that the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy was associated with an overall survival benefit in patients with stage III colorectal cancer aged ≤ 70 years but not in those aged > 70 ...
Can Baseline PSMA-PET Help to Predict Response to LuPSMA and Enzalutamide in mCRPC?
In a substudy of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that baseline prostate-specific membrane antigen (PSMA)–positron-emission tomography (PET) total tumor volume (TTV) was prognostic for overall survival and predictive for a beneficial effect on ...
Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy
In a French-Belgian phase III trial (ASTER 70s) reported in The Lancet, Brain et al examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estrogen receptor–positive, HER2-negative breast cancer with high-risk disease on the basis of genomic...
Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume
In a cross-sectional study reported in JAMA Network Open, Abel et al found that higher rates of neoadjuvant chemotherapy (NACT) and a higher annual volume of cytoreductive surgery were associated with better survival outcomes in patients treated at Commission on Cancer–accredited cancer programs in ...
Combination Therapies for Metastatic or Recurrent Pancreatic Cancer Under Study
In an interim analysis of a Japanese phase II/III trial (GENERATE, JCOG1611) reported in the Journal of Clinical Oncology, Ohba et al compared the survival benefit of mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, oxaliplatin) or S-IROX (S-1, irinotecan, oxaliplatin) vs nab-paclitaxel...
Chemotherapy Regimens Compared in High-Grade Serous Ovarian Cancer With No BRCA Mutation
In a phase III trial (EPIK-O/ENGOT-ov61) reported in the Journal of Clinical Oncology, Konstantinopoulos et al compared the survival outcomes of alpelisib plus olaparib vs single-agent chemotherapy in patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) with no...
Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers
In an Australian–New Zealand phase II trial (MoST-CIRCUIT) reported in JAMA Oncology, Gao et al found that the combination of nivolumab and ipilimumab showed “encouraging activity” in patients with advanced ovarian and endometrial clear cell cancers. Study Details Twenty-eight patients with...
Nivolumab Plus Ipilimumab in mCRPC With an Immunogenic Signature
In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signature–positive metastatic castration-resistant prostate cancer (mCRPC). Study Details The multicenter...
Outcomes Associated With COVID-19 Infection in Patients With Cancer
As reported in JAMA Oncology by Rini et al, the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) has identified outcomes associated with COVID-19 in patients with cancer. Study Details Between May 2020 and February 2022, the study enrolled adult patients from sites participating ...
Pediatric CNS Tumors: Long-Term Survival and Cure Fraction Estimates
As reported in The Lancet Oncology by Hoogendijk et al, the EUROCARE-6 population-based study has provided long-term survival rates and cure fraction estimates for pediatric patients with central nervous system (CNS) tumors across 31 European countries. Study Details The study involved data from...
Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with the FAK inhibitor defactinib in patients with recurrent low-grade serous ovarian cancer. Study...
Pembrolizumab and De-escalation of Treatment in Resectable Cutaneous Squamous Cell Cancer
In an Australian phase II trial (De-Squamate) reported in the Journal of Clinical Oncology, Ladwa et al found that the use of pembrolizumab produced a high rate of clinical or pathologic complete response in patients with resectable cutaneous squamous cell cancer (cSCC), suggesting the potential to ...
Final Overall Survival Analysis in HRR-Deficient Cohort in TALAPRO-2: Addition of Talazoparib to Enzalutamide in Metastatic CRPC
As reported in The Lancet by Fizazi et al, the final overall survival analysis in the homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (CRPC) cohort of the phase III TALAPRO-2 trial showed a significant benefit with the addition of talazoparib to...
Addition of Talazoparib to Enzalutamide in Metastatic CRPC in Genetically Unselected Cohort
As reported in The Lancet by Agarwal et al, the final overall survival analysis of the phase III TALAPRO-2 trial showed that the addition of talazoparib to enzalutamide resulted in a significant benefit in a cohort of patients with metastatic castration-resistant prostate cancer (CRPC) unselected...
Esophageal Adenocarcinoma Recurrence Patterns With Perioperative Chemotherapy vs Preoperative Chemoradiotherapy
In an analysis from the German phase III ESOPEC trial reported in the Journal of Clinical Oncology, Hoeppner et al found that perioperative chemotherapy reduced distant recurrence vs preoperative chemoradiotherapy in patients with nonmetastatic esophageal adenocarcinoma. The primary analysis of the ...
Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC
In a 4-year follow-up of the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Zhou et al examined the survival benefit of adding the PD-L1 inhibitor sugemalimab to first-line platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC) with no...
Fertility Outcomes in Patients of Childbearing Potential Receiving First-Line Therapy for Advanced Lymphoma
In an analysis reported in The Lancet Oncology, Ferdinandus et al found that among patients with newly diagnosed advanced-stage classical Hodgkin lymphoma who were of childbearing potential (POCBP) in the phase III HD21 trial, those receiving BrECADD (brentuximab vedotin, etoposide,...
Association of Type 2 Diabetes With Colorectal Cancer Risk and Survival by Tumor Immunity Status
In a German population–based, matched case-control study reported in the Journal of Clinical Oncology, Wankhede et al found that type 2 diabetes (T2D) may be associated with colorectal cancer (CRC) risk and survival according to tumor immunity status. Study Details The study included 1,889 CRC...
HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer
In an individual patient-level meta-analysis reported in The Lancet Oncology, Villacampa et al found that the HER2DX assay risk score was prognostic for event-free survival outcomes in patients with early-stage, HER2-positive breast cancer. Study Details Systematic review of the literature...
Breastfeeding Patterns After Treatment of Early Hormone Receptor–Positive Breast Cancer
In a prospective study (POSITIVE) reported in the Journal of Clinical Oncology, Peccatori et al investigated breastfeeding patterns among women who had a live birth after treatment of hormone receptor–positive breast cancer. Study Details Between December 2014 and December 2019, 518 women who...
Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Xia et al compared objective response rates seen with camrelizumab plus famitinib vs camrelizumab alone in previously treated patients with recurrent or metastatic cervical cancer. Study Details In the multicenter, open-label ...
DREAMM-7 Analysis Compares Survival Outcomes Between Triplet Regimens for Relapsed or Refractory Multiple Myeloma
In an analysis from the phase III DREAMM-7 trial reported in The Lancet Oncology, Hungria et al compared survival outcomes with belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma...
Extended Follow-up for Neoadjuvant and Adjuvant Relatlimab Plus Nivolumab in Resectable Melanoma
In an extended follow-up of a phase II trial reported in the Journal of Clinical Oncology, Burton et al examined outcomes with neoadjuvant and adjuvant relatlimab-rmbw plus nivolumab in patients with resectable melanoma. Relatlimab targets LAG3, while nivolumab targets PD-1. Study Details In the...
Thyroidectomy Without Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer
In a UK phase III trial (IoN) reported in The Lancet, Mallick et al compared survival outcomes among patients with low-risk differentiated thyroid cancer who underwent thyroidectomy with no postoperative radioiodine ablation vs thyroidectomy plus ablation. Study Details In the multicenter...
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
In an analysis from the French SAMCO-PRODIGE 54 trial reported in JAMA Oncology, Taïeb et al examined survival outcomes associated with a change in ctDNA from baseline to 1 month after start of treatment in patients receiving ICI treatment with avelumab for deficient mismatch repair/microsatellite...
Risk of Liver Cancer With Oral Contraceptive Use
In a UK population-based study reported in The Lancet Oncology, Watling et al examined the relationship between ever use vs never use of oral contraceptives and the risk of liver cancer. Some findings suggested the possibility of slightly increased risk with longer-term use. As noted by the...
Lisocabtagene Maraleucel as Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up
As reported in the Journal of Clinical Oncology by Kamdar et al, the 3-year follow-up of the phase III TRANSFORM trial showed that lisocabtagene maraleucel (liso-cel) maintained superior efficacy vs standard of care (SOC) in second-line treatment of relapsed/refractory large B-cell lymphoma (LBCL). ...
Metformin in Metastatic Prostate Cancer
In a phase III trial (part of the STAMPEDE platform) reported in The Lancet Oncology, Gillessen et al investigated the survival outcomes of adding metformin to standard of care (SOC) in nondiabetic patients with metastatic hormone-sensitive prostate cancer starting androgen-deprivation therapy...
Outcomes With Perioperative Immunotherapy in Resectable NSCLC
In a retrospective cohort study reported in JAMA Network Open, Desai et al examined survival outcomes with the addition of immunotherapy to neoadjuvant or adjuvant chemotherapy in patients with resectable non–small cell lung cancer (NSCLC). Study Details The study involved data from the Flatiron...
